CNS Pharma FY2023 net loss $18.9M; Berubicin DSMB OK, enrollment done, topline due H1 2025

CNS Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.41

Net loss $18.9M vs $15.3M in 2022; R&D expenses $14.1M (up from $9.3M) on Berubicin trial costs.
Cash at Dec 31, 2023 only $0.5M; subsequent $4.0M public offering extends runway into late Q2 2024.
Berubicin GBM study completed enrollment; DSMB recommended continue without modification after interim futility analysis.
Topline data from potentially pivotal Berubicin trial expected in first half 2025.
Appointed biotech commercialization leader Amy Mahery to Board of Directors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CNS Pharmaceuticals, Inc. reported the full year ended December 31, 2023 results: net income approximately $18.9 million.

Period: the full year ended December 31, 2023
Net income: approximately $18.9 million
Result: reported results

Exact text from the filing

The net loss for the year ended December 31, 2023 was approximately $18.9 million

View on SEC.gov

Browse all earnings releases →

CNS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-002033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.